Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Abstract Characterization of the genetic landscape of Alzheimer's disease (AD) and related
dementias (ADD) provides a unique opportunity for a better understanding of the associated …

The expeditious advancement of Alzheimer's Disease (AD) is a threat to the global
healthcare system, that is further supplemented by therapeutic failure. The prevalence of this …

Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and
together with polygenetic risk stratification can contribute towards planning of feasible and …

Background Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain
amyloidosis. Gut microbial dysbiosis in Alzheimer's disease (AD) is increasingly being …

Abstract Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification
are a “Holy Grail” of AD research and intensively sought; however, there are no well …

Introduction Blood-based biomarkers of pathophysiological brain amyloid β (Aβ)
accumulation, particularly for preclinical target and large-scale interventions, are warranted …

Importance Plasma measurement of amyloid-β (Aβ) peptides has been associated with
cognitive function, but evidence of its ability to identify cognitive decline is still scarce …

Total tau (t-tau) and phosphorylated tau (p-tau) protein elevations in cerebrospinal fluid
(CFS) are well-established hallmarks of Alzheimer's disease (AD), while the associations of …

Introduction We investigated the relationship of plasma amyloid beta (Aβ) with cerebral
deposition of Aβ and tau on positron emission tomography (PET). Methods Forty-four …